趋势的人在澳大利亚HBV或HCV通知（2000-2014）中肝癌

StephenW

J Hepatol. 2016 Aug 25. pii: S0168-8278(16)30442-1. doi: 10.1016/j.jhep.2016.08.010. [Epub ahead of print]
Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000-2014).Waziry R1, Grebely J2, Amin J2, Alavi M2, Hajarizadeh B2, George J3, Matthews GV2, Law M2, Dore GJ2.
Author information

• 1The Kirby Institute, UNSW Australia, Sydney, Australia. Electronic address: [email protected].
• 2The Kirby Institute, UNSW Australia, Sydney, Australia.
• 3Storr Liver Centre, Westmead Institute for Medical Research and Westmead Hospital, University of Sydney, Sydney, Australia.
  

AbstractBACKGROUND & AIMS: This study evaluates trends in hepatocellular carcinoma (HCC) among people with hepatitis B virus (HBV) or hepatitis C virus (HCV) infection in New South Wales (NSW), Australia between 2000 and 2014.
METHODS: Data on HBV and HCV notifications between January 1993 and December 2012 were linked to the NSW Admitted Patients Data Collection database between July 2000 and June 2014 and NSW Registry of Births Deaths and Marriages. The burden, crude and age-standardised incidence of HCC based on first hospitalization were calculated.
RESULTS: In NSW between 2000-2014, there were 54,399, 93,099 and 3,809 individuals notified with HBV, HCV and HBV/HCV coinfection respectively. There were 725 (1.3%) with HCC among those with HBV notification as compared to 1,309 with HCC (1.4%) in those with HCV notification. The population-level burden of new HCC cases per year has stabilised in the HBV cohort (53 in 2001 and 44 in 2013), but increased markedly in the HCV cohort (49 in 2001 to 151 in 2013). The age-standardised incidence rates of HCC (per 1000 person-years) declined from 2.3 (95% CI 1.4, 3.1) in 2001 to 0.9 (95% CI 0.6, 1.2) in 2012 among those with HBV and remained stable between 2001 (1.4; 95% CI 0.8, 1.9) and 2012 (1.5; 95% CI 1.2, 1.7) in those with HCV. Main factors associated with HCC in those with HBV included later study period (2005-2009; 2010-2014) (HR=0.54, 95% CI 0.42, 0.70), male gender (HR=4.50, 95% CI 3.6, 5.6), Asia-Pacific country of birth (HR=3.84, 95% CI 2.58, 5.71) and alcohol dependency (HR=2.84, 95% CI 1.95, 4.13). Main factors associated with HCC in those with HCV included male gender (HR=2.56, 95% CI 2.20, 2.98), rural place of residence (HR=0.73, 95% CI 0.62, 0.86), Asia-Pacific country of birth (HR=2.37, 95% CI 1.99, 2.82) and alcohol dependency (HR=3.90, 95% CI 3.39, 4.49).
CONCLUSION: Individual-level risk of HBV-related HCC has declined, suggesting an impact of more effective antiviral therapy from mid-2000s. In contrast, the interferon-containing HCV treatment era had no impact on individual-level HCV-related HCC risk and has seen escalating population-level HCC burden.
LAY SUMMARY: Individual-level risk of HBV-related HCC has declined, suggesting an impact of more effective antiviral therapy from mid-2000s. In contrast, the interferon-containing HCV treatment era had no impact on individual-level HCV-related HCC risk and has seen escalating population-level HCC burden.
Copyright © 2016 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.


KEYWORDS: Australia; Data linkage; Epidemiology; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma

PMID:27569777DOI:10.1016/j.jhep.2016.08.010

StephenW

肝脏病学杂志。 2016年25月PII：S0168-8278（16）30442-1。 DOI：10.1016 / j.jhep.2016.08.010。 [打印EPUB提前]
趋势的人在澳大利亚HBV或HCV通知（2000-2014）中肝癌。
Waziry R1，Grebely J2，阿明J2，阿拉维M2，Hajarizadeh B2，乔治J3，马修斯GV2，法律M2，多尔GJ2。
作者信息

    1The柯比研究所，澳大利亚新南威尔士大学，悉尼，澳大利亚。电子地址：[email protected]。
    2The柯比研究所，澳大利亚新南威尔士大学，悉尼，澳大利亚。
    3Storr肝脏中心，韦斯特米德医学研究所和Westmead医院，悉尼，澳大利亚悉尼大学。

抽象
背景与目的：

该研究评估了2000年和2014年之间的人乙型肝炎病毒（HBV）或丙型肝炎病毒（HCV）感染的新南威尔士州（NSW），澳大利亚之间的肝细胞癌（HCC）的发展趋势。
方法：

1993年1月和2012年12月间对HBV的数据和HCV通知被链接到新南威尔士州考上2000年7月和2014年6月和出生，死亡的新南威尔士州登记和婚姻之间的患者数据采集数据库。负担，原油和基于首次住院肝癌的年龄标准化发病率进行了计算。
结果：

在2000-2014之间的新南威尔士州，有54399，93099和3809人，分别HBV，HCV和HBV / HCV共感染通知。相比1309与肝癌（1.4％），在那些与HCV通知有725（1.3％）与肝癌的乙肝病毒通知中。每年新增HCC病例的人口负担水平已经稳定在HBV队列（53 2001年44 2013年），但显着的HCV队列（49，2001年到2013年151）增加。肝癌的年龄标准化发病率（每1000人年）从2.3（95％CI 1.4，3.1）于2001年在2012年的乙肝病毒之间下降到0.9（95％CI 0.6，1.2）和2001年之间保持稳定（ 1.4; 95％CI 0.8，1.9）和2012年（1.5;在那些与HCV 95％CI为1.2，1.7）。肝癌在那些与HBV相关的主要因素包括以后的学习期间（2005- 2009年; 2010- 2014年）（HR = 0.54，95％CI 0.42，0.70），男性（HR = 4.50，95％CI 3.6，5.6），出生（HR = 3.84，95％CI 2.58，5.71）和酒精依赖（HR = 2.84，95％CI 1.95，4.13）的亚太国家。肝癌在那些与HCV相关的主要因素包括男性（HR = 2.56，95％CI 2.20，2.98），农村居住地（HR = 0.73，95％CI 0.62，0.86），出生亚太国家（HR = 2.37，95％CI 1.99，2.82）和酒精依赖（HR = 3.90，95％CI 3.39，4.49）。
结论：

HBV相关HCC的个体层面的风险有所下降，这表明更有效的抗病毒治疗，从2000年代中期的影响。与此相反，含有干扰素丙肝治疗时代对个人层次的HCV相关的HCC风险没有影响，已经看到了升级群体水平的HCC负担。
LAY摘要：

HBV相关HCC的个体层面的风险有所下降，这表明更有效的抗病毒治疗，从2000年代中期的影响。与此相反，含有干扰素丙肝治疗时代对个人层次的HCV相关的HCC风险没有影响，已经看到了升级群体水平的HCC负担。

版权所有©2016年欧洲协会肝病的研究。发布时间由Elsevier B.V.保留所有权利。
关键词：

澳大利亚;数据联动;流行病学;乙型肝炎病毒;丙型肝炎病毒;肝细胞癌

结论：
    27569777
DOI：
    10.1016 / j.jhep.2016.08.010